Anti-Anxiety Drugs and Sleeping Pills doubling the Risk of Mortality

Several prescription meds linked to an increased risk of death

bmj logo image
The large study, published in BMJ, shows that several anxiolytic (anti-anxiety) drugs or hypnotic drugs (sleeping pills) are associated with a doubling in the risk of mortality.

Anti-anxiety drugs and sleeping pills have been linked to an increased risk of death, according to new research from the University of Warwick. The large study shows that several anxiolytic (anti-anxiety) drugs or hypnotic drugs (sleeping pills) are associated with a doubling in the risk of mortality. Although these findings are based on routine data and need to be interpreted cautiously, the researchers recommended that a greater understanding of their impact is essential.

Sources

  • Anti-anxiety drugs and sleeping pills linked to risk of death
    Warwick University press release, March 31, 2014
  • Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study
    BMJ 2014;348:g1996, 19 March 2014

Download the 2013 Chem Fatale Report, by Women’s Voices for the Earth

Toxic chemicals were found in pads and tampons

Chem Fatale Report front cover image
The Women’s Voices for the Earth November 2013 Chem Fatale report found toxic chemicals in feminine care products like pads and tampons.

On Flickr®

EDCs: Reproductive Effects of Early Life Exposures: The DES Example

Women exposed to DES in utero during critical periods of reproductive tract development developed several types of reproductive tract abnormalities, as well as an increased incidence of cervical-vaginal cancer later in life

2009 Study Abstract

Ovarian Follicular Development and the Environment
PubMed logo image
DES is but one example of how exposure to EDCs can disrupt developing organ systems and cause abnormalities, many of which only appear much later in life or in the subsequent generation.

The ovarian follicle is the functional unit of the ovary and is comprised of an oocyte surrounded and supported by the somatic granulosa and theca cells (28). The health of the follicle can impact the health of the woman as well as the health of her offspring. For example, decreased numbers of follicles, multiple eggs per follicle and incomplete follicular development can all result in decreased fertility. The precise mechanisms involved in early ovarian follicle formation are not known, but are essential in organizing the fetal ovary and establishing the postnatal follicle number that will provide the female with sufficient oocytes for a lifetime of fertility.

Estrogen and activin are two known factors that play an important role in regulating oocyte and follicle development and function and aberrant development and ovarian pathologies are observed in mice exposed to neonatal estrogen or activin. Neonatal exposure of rats to estradiol benzoate has been show to delay follicle and interstitial development. Neonatal exposure to diethylstilbestrol (DES) or the natural estrogen estradiol (E2) results in lack of corpora lutea in adult mice, suggesting that these effects persist beyond reproductive tract development and impact fertility in the adult. Neonatal exposure to DES, E2, or the phytoestrogen genistein also induces formation of multi-oocytic follicles in mice – an effect that is also reported in alligators exposed to environmental estrogenic contaminants. Additionally, activin administered during the critical, postnatal period of primordial follicle formation changes the number of postnatal follicles. Current mechanistic studies are exploring whether neonatal estrogen exposure alters activin signaling in the ovary; preliminary findings of decreased activin subunit gene expression and impacted activin signaling in the mouse ovary support this hypothesis.

Uterus Development and the Environment

Women exposed to DES in utero during critical periods of reproductive tract development developed several types of reproductive tract abnormalities, as well as an increased incidence of cervical-vaginal cancer later in life. Animal studies that simulate the human DES experience have since shown that exposure of the developing reproductive tract of CD-1 mice to DES imparts a permanent estrogen imprint that alters reproductive tract morphology, induces persistent expression of the lactoferrin and c-fos genes and induces a high incidence of uterine adenocarcinoma. Experiments in rats have shown exposure to DES during the critical window of uterine development leaves a hormonal imprint on the developing uterine myometrium in rats that were genetically predisposed to uterine leiomyoma, increasing the risk for adult uterine leiomyoma from 65% to greater than 90% and increasing tumor multiplicity and size. DES-induced developmental programming appears to require the estrogen receptor α , suggesting that signaling through this receptor is crucial for establishing developmental programming.

Studies have now been extended beyond DES to demonstrate that other environmental estrogens reprogram gene expression in the uterus : exposure to genistein and BPA during the period of maximum sensitivity to developmental programming induces the expression of the estrogen-responsive genes calbindin and progesterone receptor. Neonatal BPA exposure attenuated estrogen-responsive genes whereas genistein exposure induced an even higher level of estrogen responsiveness than DES exposure. In contrast to DES, exposure to these environmental estrogens does not disrupt ovarian function in adult females, which continue to cycle normally.

Sources
  • PMC, Proceedings of the Summit on Environmental Challenges to Reproductive Health and Fertility: executive summary, PMC2440710, Feb 1, 2009.
More DES DiEthylStilbestrol Resources

The Health and Environment Alliance HEAL re-launched the Chemicals Health Monitor CHM

The Chemicals Health Monitor aims to be your online source for the link between chemicals and diseases

Press release:

image of Health and Environment Alliance logo
The Chemicals Health Monitor aims to be your online source for the link between chemicals and diseases.

” The Health and Environment Alliance (HEAL) has today re-launched its Chemicals Health Monitor (CHM), a revived online service consisting of a revamped website and newsletter as well as new social media tools, all available in English and German.

HEAL provides this monitoring service with the aim of improving public health by promoting support for more protective regulation of hazardous chemicals in Europe and beyond. The project encourages public health and health professional groups to use and share educational resources to inform patients and the public.

Many of the chemicals to which people are exposed daily have never been tested for their effects on human health and the environment. When studies have been done, the test results may not be publicly available. Meanwhile, more and more studies link chemical exposure to a range of specific chronic conditions. The research suggests that due to their exposure, families and individuals may be more prone to obesity and diabetes, more likely to suffer from cancer, and more likely to face infertility. Healthcare systems are struggling to cope with rising rates of these conditions.

Although EU laws set high and innovative standards, significant gaps nonetheless remain, particularly regarding the effects of multiple concurrent exposures and of long-term, cumulative exposures. The Chemicals Health Monitor provides the latest authoritative, independent information linking chemical exposure to chronic health problems, which is developed with the help of public interest expertise.

HEAL’s ultimate goal in providing such a service is to inform the public and to mobilise partnerships in support of EU policies that protect health. In particular, HEAL seeks precautionary action to prevent exposure to toxic chemicals and effective implementation of the EU chemicals law, REACH.”

Sources: HEAL Blog, Brussels, 25 March 2014 – Follow on  Twitter

Guide des 4000 médicaments utiles, inutiles ou dangereux

Les professeurs Bernard Debré et Philippe Even ont rué dans les brancards

image du livre Guide-des-4000-medicaments
Après de violentes critiques de la part d’éminents médecins partout en France, les professeurs Bernard Debré et Philippe Even ont été sanctionnés pour leur guide sur les médicaments.

Après les affaires de l’hormone de croissance, du Vioxx, de l’Isoméride du Mediator, et de plusieurs médicaments retirés du marché en quelques mois, une véritable, mais salutaire inquiétude s’est manifestée dans la population concernant l’utilité et les risques des traitements. La publication soudaine de listes de médicaments “sous surveillance renforcée”, dont beaucoup, inutiles ou dangereux, devraient avoir disparu depuis longtemps, souligne la timidité ou l’incompétence des pouvoirs publics et a fait monter d’un cran l’anxiété des patients. Les professeurs Even et Debré ont donc décidé de passer en revue les 4.000 médicaments sur le marché et d’identifier ceux qui sont efficaces, ceux qui le sont moins, ceux qui ne le sont pas du tout et, parallèlement, d’analyser leur degré de toxicité éventuelle intrinsèque et celle qui pourrait résulter des interactions entre eux, de l’âge des malades et des pathologies associées et préciser quel pays les a découverts, leur prix et leur coût pour la Sécurité Sociale. Ce guide, écrit pour les malades et parfois les médecins généralistes, ne peut évidemment répondre dans le détail à toutes les questions, mais il peut alerter, aider et, en cas de doute, conduire à consulter son médecin. Il devrait aussi aider les politiques à revoir et contrôler réellement le monde délirant des médicaments, ses milliers de médicaments inutiles, ses centaines dangereux.

Lire les commentaires en ligne et ces quelques articles de presse:

  • Pétition: Soutien aux Prs. Debré et Even qui dénoncent la corruption des laboratoires pharmaceutiques! MesOpinions, 20/03/2014
  • Big Pharma : Les Pr Even et Debré sanctionnés pour leur guide sur les médicaments, Chaos-Controle, 19 mars 2014
  • Les professeurs Philippe Even et Bernard Debré interdits d’exercer la médecine pendant un an, Le Monde, 18 mars 2014
  • Les 56 médicaments dangereux ou inutiles, Le Figaro, 13 sept 2012
  • Un livre choc dénonce l’excès de médicaments inutiles, Le Figaro, 13 sept 2012

En savoir plus sur ce Sujet

Sur Flickr®

Clear and direct new Evidence that Autism begins during Pregnancy

New clues suggesting autism could be detected before birth

Researchers found new clues suggesting autism could be detected before birth ; their study gives clear and direct new evidence that autism begins during pregnancy. The researchers analyzed 25 genes in post-mortem brain tissue of children with and without autism. These included genes that serve as biomarkers for brain cell types in different layers of the cortex, genes implicated in autism and several control genes. Patches of unusual cell development was found in 10 samples.

More info and Videos
  • Video by UC San Diego Health System, Published on 26 Mar 2014.
  • In their small, explorative study – Patches of Disorganization in the Neocortex of Children with Autism – researchers found focal disruption of cortical laminar architecture in the cortexes of a majority of young children with autism.
  • Read Patches of Cortical Layers Disrupted During Early Brain Development in Autism, University of California, San Diego, News Release March 26, 2014
  • Read Patches of Disorganization in the Neocortex of Children with Autism, N Engl J Med 2014; 370:1209-1219 March 27, 2014DOI: 10.1056/NEJMoa1307491
  • Watch more videos on our YouTube channel.

Doctors’ Strike: what’s written?

Finding medical records showing that DES was prescribed during pregnancy can be very difficult…

Comics image of Doctors' strike

Can you understand your doctor’s handwriting? For DES daughters, finding medical records showing that their mums were prescribed DES during pregnancy can be very difficult. If the doctor has retired or died, another doctor may have taken over the practice as well as the records or if the records are found they may just be unreadable …!

On Flickr®

Procès Distilbène Stéphanie 2014: rendu des délibérés le 22 mai prochain

Procès Distilbène UCB Pharma: trois semaines après la victoire de Sylvie Le Cossec, le tribunal de Nanterre a annonçé que le rendu des délibérés pour Stéphanie aura lieu le 22 2014

stephanie chevallier
Stéphanie est présidente de l’association
Les Filles DES.

Stéphanie Chevallier – auteure du livre Moi, Stephanie, Fille DistilbèneLe Scandale de la Maternité volée… , présidente de l’association Les Filles DES,  dont voici une vidéo d’archive 2009 – a enfin eu son dossier plaidé au Tribunal de Nanterre après plus de neuf ans d’attente au total .

A cause de son exposition in utero au Distilbène, Stéphanie souffre de problèmes de stérilité et de malformations utérines qui l’ont notamment privée du bonheur de donner la vie. En 2005, elle engage une procédure judiciaire contre le laboratoire UCB Pharma qui commercialisait le DES. Son procès n’aura pas lieu car UCB Pharma fait annuler la demande d’expertise médicale en appel. Puis, en 2009, la Cour de Cassation annonce qu’il est interdit de faire appel d’une telle demande. Le dossier de Stéphanie peut donc être plaidé et jugé. Mais la lenteur de la justice française la contraint à attendre cinq ans de plus pour que le procès s’ouvre enfin.

Trois semaines après la victoire de Sylvie Le Cossec, le tribunal de Nanterre a annonçé que le rendu des délibérés pour Stéphanie aura lieu le 22 mai prochain.

Mai 2014 : le labo UCB Pharma à nouveau condamné.
Octobre 2016 – cour d’appel : Une «fille Distilbène» obtient réparation sans avoir à fournir d’ordonnance.

Le Distilbène DES, en savoir plus

EDCs : Developmental Programming and Fetal Origins of Adult Disease ; The DES Diethylstilbestrol Example

Proceedings of the Summit on Environmental Challenges to Reproductive Health and Fertility

Abstract

PubMed logo image
DES is but one example of how exposure to EDCs can disrupt developing organ systems and cause abnormalities, many of which only appear much later in life or in the subsequent generation.

Prenatal exposure to diethylstilbestrol (DES), a synthetic estrogen and thus EDC, provides an unfortunate example of developmental programming. DES was given to U.S. pregnant women between 1938 and 1971 under the erroneous assumption that it would prevent pregnancy complications. In fact, in utero exposure to DES alters the normal programming of gene families, such as Hox and Wnt, that play important roles in reproductive tract differentiation. As a result, female offspring exposed to DES in utero are at increased risk of clear cell adenocarcinoma of the vagina and cervix, structural reproductive tract anomalies, infertility and poor pregnancy outcomes, while male offspring have an increased incidence of genital abnormalities and a possibly increased risk of prostate and testicular cancer. These observed human effects have been confirmed in numerous animal models which have also provided information on the toxic mechanisms of DES. Animal experiments have also predicted changes later found in DES-exposed humans, such as oviductal malformations, increased incidence of uterine fibroids and second-generational effects such as increased menstrual irregularities and possibly ovarian cancer in DES-granddaughters and increased hypospadias in DES-grandsons.

DES is but one example of how exposure to EDCs can disrupt developing organ systems and cause abnormalities, many of which only appear much later in life or in the subsequent generation, such as endometriosis, fibroids and breast, cervical and uterine cancer in women; poor sperm quality and increased incidence of cryptorchidism and hypospadias in men; and subfertility and infertility in men and women.

Sources
  • NCBI, PMID: 18275883, 2008 Feb;89(2):281-300. doi: 10.1016/j.fertnstert.2007.10.002.
  • PMC, Proceedings of the Summit on Environmental Challenges to Reproductive Health and Fertility: executive summary, PMC2440710, Feb 1, 2009.
More DES DiEthylStilbestrol Resources

FDA tries to regulate Health Apps

#FDA works to gain the jurisdiction to regulate health related mobile apps. #HealthApps

FDA works to gain the jurisdiction to regulate health related mobile apps.

More info and Videos